Introduction
Multiple myeloma (MM) is the most common indication requiring high-dose therapy and autologous stem cell transplantation (ASCT), 1 which have significantly improved response rate, progression-free and overall survival compared with conventional chemotherapy. [2] [3] [4] Successful peripheral blood stem cell (PBSC) mobilization remains a key factor for ASCT. Mobilization is usually achieved with hematopoietic stem cell-sparing chemotherapy plus growth factors. [5] [6] [7] Risk factors for impaired stem cell collection include previous radiotherapy exposure at bone marrow containing sites in the adult (pelvis and spine), prolonged chemotherapy with stem cell toxic alkylating agents (melphalan, busulfan and nitrosoureas), extensive bone marrow infiltration and mobilization strategy. [8] [9] [10] [11] [12] The introduction of effective agents to treat MM, such as thalidomide, bortezomib and lenalidomide, results in high response rates, and may allow delaying transplantation to initial relapse. [13] [14] [15] [16] [17] [18] [19] Recent reports have focused on the impact of these novel induction regimens on stem cell mobilization. [20] [21] [22] [23] [24] [25] [26] [27] [28] There are contradictory data regarding the effect of thalidomide. 20, 23, 24 Most of the reported trial data show a lower stem cell harvest in patients treated with thalidomide compared with control groups who received dexamethasone or dexamethasone-doxorubicin induction regimens; the median stem cell yield in the thalidomide-treated patients ranged from 7.4 to 10.0 Â 10 6 CD34 þ /kg, whereas in the control groups, the median stem cell yield ranged from 9.4 to 10.9 Â 10 6 CD34 þ /kg. 20, 23, 24 However, overall most groups reported sufficient stem cell yield from patients treated with thalidomide for a single ASCT. The effect of bortezomib on the ability to collect PBSC has also been examined in the context of clinical trials. 25, 28, 29 In a randomized trial, there was a trend toward a lower stem cell number in patients who received bortezomibdexamethasone; median yield was 6.8 Â 10 6 CD34 þ /kg in the bortezomib group versus 8.5 Â 10 6 CD34 þ /kg in the control group receiving vincristine-doxorubicin-dexamethasone (VAD). 25 In another randomized trial, bortezomib-doxorubicin-dexamethasone did not have any negative impact, and the median yield of stem cell harvested was 10.48 Â 10 6 CD34 þ /kg. 29 The hematological toxicity observed during treatment with lenalidomide has raised concern that its use may negatively impact the ability to mobilize stem cells. [20] [21] [22] 27 Median yield of stem cells collected after lenalidomide-dexamethasone (Rd) induction ranged from 3.1 to 7.9 Â 10 6 CD34 þ /kg in patients mobilized with granulocyte colony-stimulating factor (G-CSF) alone. [20] [21] [22] 26, 27 By contrast, the median yield of stem cells ranged from 6.3 to 14.2 Â 10 6 CD34 þ /kg in patients mobilized with cyclophosphamide plus G-CSF. [20] [21] [22] 26, 27 These data clearly show that a cyclophosphamide plus G-CSF mobilization strategy can significantly increase the yield of stem cells harvested. In a multicenter, prospective study (RV-MM-PI209) of patients with newly diagnosed MM, Rd was used as induction, patients were then mobilized and randomized to receive oral melphalan-prednisone-lenalidomide or high-dose melphalan and tandem ASCT. In this trial, we investigate the influence of Rd on stem cell collection.
Materials and methods

Patient selection criteria
Patients eligible for the RV-MM-PI209 trial (http://clinicaltrials. gov: NCT00551928) were required to have newly diagnosed symptomatic MM with measurable disease, 30 be aged p65 years, have a Karnofsky performance status score of 60% or more and a life expectancy of more than 6 months. The study was approved by the institutional review boards or the ethics committees of each participating center, and written informed consent was obtained from each patient before the study in accordance with the Declaration of Helsinki. Exclusion criteria were previous treatment for MM; abnormal cardiac, pulmonary, renal or hepatic functions; seropositivity for human immunodeficiency virus, hepatitis C or hepatitis B; and active nonhematological malignancies. We analyzed the stem cell collection data in patients who had completed the mobilization phase.
Induction chemotherapy regimens, stem cell mobilization and autografting
In the RV-MM-PI209 trial, induction treatment comprised four cycles of oral lenalidomide at a dose of 25 mg/day for days 1-21 of each 28-day cycle in combination with oral dexamethasone at a dose of 40 mg/day on days 1, 8, 15 and 22 of each 28-day cycle of Rd. At 1 to 2 months after completion of the last induction cycle, stem cells were mobilized with intravenous cyclophosphamide (4 g/m 2 per day) on day 1 and G-CSF (10 mg/ kg per day) starting 5 days after the end of cyclophosphamide therapy until the end of stem cell collection. The harvest was initiated when white blood cell counts were 41000/ml and CD34 þ counts in peripheral blood were 410/ml. All centers involved in the trial used the same apheresis technique. Apheretic collections were performed with an automated continuous-flow blood cell separator. A volume of 2 to 10 l of blood was processed for each collection. Collection continued until target yields of 4 Â 10 6 CD34 þ /kg were achieved. Patients who failed to collect the target CD34 þ yields received a second course of cyclophosphamide plus G-CSF for a second mobilization attempt. Patients who continued to fail to collect the target yields after the second cyclophosphamide plus G-CSF course did not proceed to ASCT. After at least 1 month from PBSC collection, autografting consisted of melphalan at 200 mg/m 2 on day À2 and cryopreserved PBSC infusion on day 0. Patients received G-CSF at a dose of 5 mg/kg from day 3 until neutrophil count 41000/ml was achieved. Data on age, gender, stem cell counts, MM markers (serum and urinary M protein levels), standard prognostic parameters (serum levels of creatinine, b2-microglobulin, serum albumin and lactate dehydrogenase) and percentage of bone marrow plasma cells were collected. Hematological and non-hematological toxicities were assessed and scored according to the National Cancer Institute Common Terminology Criteria (version 3.0). 31 The total yield of CD34 þ cells, the number of collections performed and the days of leukapheresis were recorded in all patients. Data on engraftment after ASCT were collected; neutrophil engraftment was defined as the first day with an absolute neutrophil count of at least 500 Â 10 9 /l after post-ASCT nadir. Platelet engraftment was determined as the first day with a platelet count of at least 25 Â 10 9 /l and absence of platelet transfusion.
Statistical analysis
A favorable CD34 þ mobilization (X4 Â 10 6 cells/kg) was used as a dependent variable in univariate and multivariate binary logistic regression models, testing age at diagnosis (over 60 versus under 60 years), gender (male versus female), b 2 -microglobulin (X3.5 versus o3.5 mg/l), baseline hemoglobin (X10 versus o10 g/dl), baseline platelets count (X150 Â 10 9 /l versus o150 Â 10 9 /l), hematological and extrahematological toxicity during mobilization (Xgrade 3-4 versus ograde 3-4). Odds ratios (ORs) and corresponding 95% confidence intervals were reported. 32 All reported P-values are two-sided at the conventional 5% significance level. Data were analyzed as of November 2010 using SAS software (version 8.2) and SPSS 18.0.2 (SPSS Inc., Chicago, IL, USA) packages.
Results
Patient characteristics and stem cell collection
Patient characteristics are listed in Table 1 . A total of 331 patients were evaluable for stem cell collection. The median age at the time of stem cell collection was 57 years (range, 32-65 years); 55% of patients were male. Patients received the first mobilization cycle with cyclophosphamide plus G-CSF after a median (from the end of induction) of 37 days. Median time from cyclophosphamide plus G-CSF and leukapheresis was 11 days (range, 7-34 days). The median days of leukapheresis was 3 days. A second mobilization was required for inadequate Lenalidomide and stem cell mobilization F Cavallo et al yield, which was defined as o4 Â 10 6 CD34 þ /kg, in 21% of patients. After this second procedure, 91% of patients had yields of at least 4 Â 10 6 CD34 þ /kg and, therefore, could receive tandem ASCT. At the end of the second mobilization, 8% of patients had yields of o2 Â 10 6 CD34 þ /kg precluding ASCT. The total median yields of 8.7 Â 10 6 CD34 þ /kg (range, 0-73 Â 10 6 CD34 þ /kg) were obtained (Table 2a) . 
Hematopoietic reconstitution after first ASCT
CD34
þ /kg) cells were infused during the first ASCT procedure (Table 2b ). The engraftment was rapid and the number of days to neutrophil engraftment (defined as neutrophils 4500 Â 10 9 /l) or platelet engraftment (defined as 425 Â 10 9 /l) was not influenced by number of CD34 þ cells infused (data not shown). A total of 63% of patients required red blood cell or platelet transfusions during ASCT. No patients received o2 Â 10 6
þ /kg, as this was considered an exclusion criterion for ASCT.
In an univariate pooled analysis, age 460 years (P ¼ 0.012), a baseline hemoglobin value of o10 g/dl (P ¼ 0.002) and occurrence of grade 3-4 anemia after mobilization (P ¼ 0.002) were found to be associated with collection of o4 Â 10 6 CD34 þ /kg cells. In a multivariate pooled analysis, the only factor that was confirmed to affect the CD34 yield was a baseline hemoglobin value of o10 g/dl (OR 3.99; P ¼ 0.002; Table 3 ).
Discussion
In this study, we investigated the influence of lenalidomide on the stem cell collection in newly diagnosed MM patients before ASCT. The introduction of the novel agents, thalidomide, bortezomib and lenalidomide, have induced high rates of complete and very good partial responses, prompting their use as integral components of induction regimens. [13] [14] [15] [16] [17] [18] [19] Different studies have evaluated the impact of induction therapy with novel agents on stem cell collection. There are contradictory data on the impact of thalidomide on stem cell mobilization and collection. Several groups have focused on stem cell yield following thalidomide administration, suggesting that thalidomide diminishes the yield of stem cell in the range of 10-25% in comparison with control groups. 23, 24 Overall, most groups reported sufficient stem cell harvest from patients treated with thalidomide for a single ASCT. 23, 24 Other studies have evaluated the impact of bortezomib on the ability to collect stem cells and modest or no reduction in the yield of stem cells were reported in comparison with controls. 25, 28, 29 Myelosuppression is one of the common adverse effects of lenalidomide, and this finding has raised concern about its potential adverse effect on stem cell mobilization. In the different retrospective published trials on lenalidomide induction, the median yield of PBSC ranged from 6.3 Â 10 6 CD34 þ /kg to 14.2 Â 10 6 CD34 þ /kg in patients mobilized with cyclophosphamide plus G-CSF. [20] [21] [22] 26, 27 This variation in mobilization failure rate following lenalidomide therapy between the different studies probably reflects the variations in lenalidomide treatment duration, age of the patient population undergoing stem cell collection, mobilization regimens and collection Abbreviations: CI, confidence interval; OR, odds ratio. a Multivariate analysis was performed on the significant variables found at the univariate analysis.
Lenalidomide and stem cell mobilization F Cavallo et al targets used. It has been suggested that cyclophosphamide and G-CSF should be used for mobilization in patients receiving more than four cycles of lenalidomide therapy. 33 In our study, cyclophosphamide plus G-CSF mobilized a median of 8.7 Â 10 6
CD34
þ /kg cells. The median yield of stem cell collected in the our study is consistent with that observed in other Rd studies. [20] [21] [22] 26, 27 Ninety-one percent of patients were able to obtain, at the end of the mobilization phase, sufficient stem cell harvests. The introduction of a second mobilization procedure with cyclophosphamide plus G-CSF is an appropriate strategy to rescue poor mobilizers and to collect an appropriate number of stem cell in the vast majority of patients. In our group, 21% of patients did not reach the target yield of 4 Â 10 6 CD34 þ /kg after the first cyclophosphamide plus G-CSF cycle; however, after the second cycle this was reduced to 9%. Therefore, our report confirms the low collection failure among patients mobilized with cyclophosphamide plus G-CSF. 26, 34 The use of cyclophosphamide plus G-CSF might contribute to cytoreduction, and this is an advantage in comparison with G-CSF alone. Disadvantages may include hospitalization and higher incidence of neutropenic fever. In this study, the use of intermediate dose of cyclophosphamide allowed drug administration in the outpatient setting, and did not increase the need for hospitalization for adverse events (data not shown).
The rapid response seen with novel agent combinations allows early stem cell mobilization to be performed after three to four cycles of initial therapy. In our study, four courses of Rd were delivered before stem cell mobilization, and a median of 37 days (range, 3-94 days) occurred between the end of lenalidomide and cyclophosphamide administration. The four courses of Rd and the 30 days off therapy before mobilization seem adequate to perform a successful mobilization. The routine use of AMD3100 in patients who fail to collect adequate PBSC yields after cyclophosphamide plus G-CSF therapy has yet to be evaluated in a prospective manner, but it may be considered in selected patients because it has been very successful in mobilizing stem cells in combination with G-CSF. 33, 35, 36 The exact mechanism why lenalidomide inhibits stem cell mobilization is unclear. Koh et al. 37 investigated the effects of lenalidomide, pomalidomide (CC-4047; IMiDs immunomodulatory drugs, Celgene Corportion, Summit, NJ, USA) and thalidomide on CD34 þ hematopoietic progenitors. They showed that the IMiDs immunomodulatory drugs and thalidomide are not toxic to hematopoietic stem cells, but that IMiD immunomodulatory drugs promote myelopoiesis with a concomitant maturation stop of neutrophil granulocytes by the downregulation of crucial transcription factors such as PU.1, thus leading to an accumulation of immature granulocytes within the bone marrow compartment. 38 Koh et al. 37 also observed that the G-CSF secretion was highly upregulated in cultures of hematopoietic progenitors treated with IMiD immunomodulatory drugs, but the biological reason for this finding is unknown. We evaluated factors possibly affecting stem cell mobilization and collection. A baseline hemoglobin level of o10 g/dl significantly correlated with a higher risk of inadequate stem cell mobilization. Anemia reflects extensive bone marrow infiltration that is usually associated with poor stem cell reserve. In our study, all patients were younger than 65 years of age, and a trend for higher risk of mobilization failure was observed in patients aged older than 60 years, but this difference was not significant, possibly because of the small number of true elderly patients included in the study.
In conclusion, lenalidomide as part of an induction regimen did not adversely affect the stem cell mobilization. The quantity of stem cells collected was adequate to perform tandem ASCT in 91% of patients with rapid and successful engraftment in all patients. This is the largest prospective study reporting on stem cell collection after Rd induction before ASCT in patients with newly diagnosed MM.
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